Acute inhibition of the endogenous xanthine oxidase improves renal hemodynamics in hypercholesterolemic pigs

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 290, Issue 3, 2006, Pages

  Daghini, Elena ^a   Chade, Alejandro R ^a   Krier, James D ^a   Versari, Daniele ^a   Lerman, Amir ^a   Lerman, Lilach O ^a  

^a Mayo Clinic   (United States)

Author keywords

Endothelium; Oxidative stress; Oxypurinol; Uric acid

Indexed keywords

ACETYLCHOLINE; ISOPROSTANE; LOW DENSITY LIPOPROTEIN; NITROPRUSSIDE SODIUM; OXIPURINOL; URIC ACID; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON BEAM TOMOGRAPHY; ENDOTHELIUM; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; GLOMERULUS FILTRATION; HYPERCHOLESTEROLEMIA; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL; ANIMAL; CHOLESTEROL INTAKE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; KIDNEY; KIDNEY CIRCULATION; METABOLISM; PATHOPHYSIOLOGY; SWINE; TREATMENT OUTCOME; VASCULARIZATION;

ANIMALS; CHOLESTEROL, DIETARY; FEMALE; HYPERCHOLESTEROLEMIA; KIDNEY; OXYPURINOL; RENAL CIRCULATION; SWINE; TREATMENT OUTCOME; XANTHINE OXIDASE;

EID: 33645409484     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00436.2005     Document Type: Article

References (53)

1. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults final report. Circulation 106: 3143-3421, 2002.
2. Agarwal A, Balla J, Balla G, Croatt AJ, Vercellotti GM, and Nath KA. Renal tubular epithelial cells mimic endothelial cells upon exposure to oxidized LDL. Am J Physiol Renal Fluid Electrolyte Physiol 271: F814-F823, 1996.
3. Baud L and Ardaillou R. Involvement of reactive oxygen species in kidney damage. Br Med Bull 49: 621-629, 1993.
4. Berry CE and Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589-606, 2004.
5. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, and Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1842-1847, 1998.
6. Cardillo C, Kilcoyne CM, Cannon RO, 3rd Quyyumi AA, and Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 30: 57-63, 1997.
7. Chade AR, Bentley MD, Zhu X, Rodriguez-Porcel M, Niemeyer S, Amores-Arriaga B, Napoli C, Ritman EL, Lerman A, and Lerman LO. Antioxidant intervention prevents renal neovascularization in hypercholesterolemic pigs. J Am Soc Nephrol 15: 1816-1825, 2004.
8. Chade AR, Herrmann J, Zhu X, Krier JD, Lerman A, and Lerman LO. Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. J Am Soc Nephrol, 16: 1005-1012, 2005.
9. Chade AR, Krier JD, Rodriguez-Porcel M, Breen JF, McKusick MA, Lerman A, and Lerman LO. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease. Am J Physiol Renal Physiol 286: F1079-F1086, 2004.
10. Chade AR, Rodriguez-Porcel M, Grande JP, Krier JD, Lerman A, Romero JC, Napoli C, and Lerman LO. Distinct renal injury in early atherosclerosis and renovascular disease. Circulation 106: 1165-1171, 2002.
11. Chade AR, Rodriguez-Porcel M, Rippentrop SJ, Lerman A, and Lerman LO. Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia. Am J Hypertens 16: 111-115, 2003.
12. Chin JH, Azhar S, and Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 89: 10-18, 1992.
13. Chowienczyk PJ, Watts GF, Cockcroft JR, and Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 340: 1430-1432, 1992.
14. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, and Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 86: 228-234, 1990.
15. Day RO, Miners J, Birkett DJ, Graham GG, and Whitehead A. Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol. Br J Clin Pharmacol 26: 429-434, 1988.
16. Ding G, van Goor H, Ricardo SD, Orlowski JM, and Diamond JR. Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int 51: 147-154, 1997.
17. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, and Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105: 2619-2624, 2002.
18. Drexler H, Zeiher AM, Meinzer K, and Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 338: 1546-1550, 1991.
19. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Muller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, and Landmesser U. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110: 2175-2179, 2004.
20. Feldstein A, Krier JD, Sarafov MH, Lerman A, Best PJ, Wilson SH, and Lerman LO. In vivo renal vascular and tubular function in experimental hypercholesterolemia. Hypertension 34: 859-864, 1999.
21. Flores OR, Sun L, Vaziri ND, and Miyada DS. Colorimetric rate method for the determination of creatinine as implemented by the Beckman Creatinine Analyzer 2. Am J Med Technol 46: 792-798, 1980.
22. Fried LF, Orchard TJ, and Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59: 260-269, 2001.
23. -. in posthypoxic injury of renal epithelial cells. Am J Physiol Renal Fluid Electrolyte Physiol 263: F251-F255, 1992.
24. Grone EF, Walli AK, Grone HJ, Miller B, and Seidel D. The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 107: 1-13, 1994.
25. Grone HJ, Hohbach J, and Grone EF. Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl 54: S18-S22, 1996.
26. Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, and Mark AL. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res 54: 711-718, 1984.
27. Ito T, van Kuilenburg AB, Bootsma AH, Haasnoot AJ, van Cruchten A, Wada Y, and van Gennip AH. Rapid screening of high-risk patients for disorders of purine and pyrimidine metabolism using HPLC-electrospray tandem mass spectrometry of liquid urine or urine-soaked filter paper strips. Clin Chem 46: 445-452, 2000.
28. John S and Schmieder RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep 5: 199-207, 2003.
29. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, and Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41: 1183-1190, 2003.
30. Keane WF. Lipids and the kidney. Kidney Int 46: 910-920, 1994.
31. Krier JD, Ritman EL, Bajzer Z, Romero JC, Lerman A, and Lerman LO. Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function. Am J Physiol Renal Physiol 281: F630-F638, 2001.
32. Krier JD, Rodriguez-Porcel M, Best PJ, Romero JC, Lerman A, and Lerman LO. Vascular responses in vivo to 8-epi PGF(2alpha) in normal and hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol 283: R303-R308, 2002.
33. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, and Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344: 160-162, 1990.
34. Laakso JT, Teravainen TL, Martelin E, Vaskonen T, and Lapatto R. Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens 22: 1333-1340, 2004.
35. Lee HS, Jeong JY, Kim BC, Kim YS, Zhang YZ, and Chung HK. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int 51: 1151-1159, 1997.
36. Lee HS and Kim YS. Identification of oxidized low-density lipoprotein in human renal biopsies. Kidney Int 54: 848-856, 1998.
37. Luscher TF, Tanner FC, and Dohi Y. Age, hypertension and hypercholesterolaemia alter endothelium-dependent vascular regulation. Pharmacol Toxicol 70: S32-S39, 1992.
38. Maxwell AJ and Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol 38: 1850-1858, 2001.
39. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, and Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991-F997, 2002.
40. Mori T and Cowley AW Jr. Angiotensin II-NAD(P)H oxidase-stimulated superoxide modifies tubulovascular nitric oxide cross-talk in renal outer medulla. Hypertension 42: 588-593, 2003.
41. O'Driscoll JG, Green DJ, Rankin JM, and Taylor RR. Nitric oxide-dependent endothelial function is unaffected by allopurinol in hypercholesterolaemic subjects. Clin Exp Pharmacol Physiol 26: 779-783, 1999.
42. Rodriguez-Porcel M, Krier JD, Lerman A, Sheedy PF 2nd, Romero JC, Napoli C, and Lerman LO. Combination of hypercholesterolemia and hypertension augments renal function abnormalities. Hypertension 37: 774-780, 2001.
43. Rodriguez-Porcel M, Lerman A, Best PJ, Krier JD, Napoli C, and Lerman LO. Hypercholesterolemia impairs myocardial perfusion and permeability: role of oxidative stress and endogenous scavenging activity. J Am Coll Cardiol 37: 608-615, 2001.
44. Rodriguez-Porcel M, Lerman LO, Holmes DR Jr, Richardson D, Napoli C, and Lerman A. Chronic antioxidant supplementation attenuates nuclear factor-kappa B activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res 53: 1010-1018, 2002.
45. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
46. Sellke FW, Armstrong ML, and Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 81: 1586-1593, 1990.
47. Short RA, Johnson RJ, and Tuttle KR. Uric acid, microalbuminuria and cardiovascular events in high-risk patients. Am J Nephrol 25: 36-44, 2005.
48. Stocker R and Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381-1478, 2004.
49. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, and Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 99: 41-46, 1997.
50. Stulak JM, Lerman A, Porcel MR, Caccitolo JA, Romero JC, Schaff HV, Napoli C, and Lerman LO. Renal vascular function in hypercholesterolemia is preserved by chronic antioxidant supplementation. J Am Soc Nephrol 12: 1882-1891, 2001.
51. Turnheim K, Krivanek P, and Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 48: 501-509, 1999.
52. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, and Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci USA 93: 8745-8749, 1996.
53. Wilson SH, Best PJ, Lerman LO, Holmes DR Jr, Richardson DM, and Lerman A. Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-prostaglandinF2 alpha, in experimental hypercholesterolemia. Cardiovasc Res 44: 601-607, 1999.